ReviewFrontiers in pharmacology2023
Infection with
Review in Frontiers in pharmacology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 33 citations in OpenAlex.
- Beyond the gut: a comprehensive meta-analysis on Helicobacter pylori infection and cardiovascular complications.Annals of clinical microbiology and antimicrobials · 2025Pooled it
- Causal associations between antibody-mediated immune responses to infectious agents and cardiovascular inflammatory diseases: A Mendelian randomization study based on UK Biobank and FinnGen.Human vaccines & immunotherapeutics · 2026Article
- 7-O-methylpunctatin is a potential inhibitor of human arachidonate 5-lipoxygenase: molecular and structural insights into anti-atherosclerosis therapeutics.Molecular diversity · 2026Article
- Analysis of clinical features of lupus mesenteric vasculitis.Clinical and experimental medicine · 2026Article
- Impact ofJournal of clinical medicine · 2026Article
- Pathological mechanisms of inflammatory responses in atherosclerosis and the multi-target regulatory effects of traditional Chinese medicine.Frontiers in cardiovascular medicine · 2026Review
- HELICOBACTER PYLORI BEYOND THE STOMACH: WHEN THE STORY CHANGES.Arquivos de gastroenterologia · 2026Review
- Relationship BetweenCardiology research and practice · 2026Article
- Bacterial extracellular vesicles in the initiation, progression and treatment of atherosclerosis.Gut microbes · 2025Review
- Article
- Article
- Association ofJGH open : an open access journal of gastroenterology and hepatology · 2025Review
- Extracellular vesicles in Helicobacter pylori-mediated diseases: mechanisms and therapeutic potential.Cell communication and signaling : CCS · 2025Review
- Involvement of Lipids and Lipid Mediators in Inflammation and Atherogenesis.Current medicinal chemistry · 2025Review
- Article
- Article
- The pharmaco-epigenetics of hypertension: a focus on microRNA.Molecular and cellular biochemistry · 2024Review
- 1,3,6-Trigalloylglucose: A Novel Potent Anti-Molecules (Basel, Switzerland) · 2024Article
- The Effects of Red Palm Oil, Koja Bay Leaves, and Passion Fruit Seeds Formulation on Antioxidant Activity, Antihyperlipidemia, BDNF, and Lipase Enzyme Activity on Sprague-Dawley Rats.Journal of experimental pharmacology · 2024Article
- The Gastric Connection: Serum Gastric Biomarkers, Metabolic Syndrome and Transition in Metabolic Status.Journal of inflammation research · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Atherosclerosis is a major instigator of cardiovascular disease (CVD) and a main cause of global morbidity and mortality. The high prevalence of CVD calls for urgent attention to possible preventive measures in order to curb its incidence. Traditional risk factors of atherosclerosis, like age, smoking, diabetes mellitus, dyslipidemia, hypertension and chronic inflammation, are under extensive investigation. However, these only account for around 50% of the etiology of atherosclerosis, mandating a search for different or overlooked risk factors. In this regard, chronic infections, by
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.